Significant skin clearance in 3 pivotal trials1,3
Concomitant therapy with TCS
easi-75 AT
WEEKs 16 AND
52
(secondary endpoints)2,4,a-c
Definitive conclusions cannot be made at Week 2, as this was a post hoc analysis. Data
were not multiplicity
controlled and P value was nominal.
Significant improvement in lesion extent and severity was also demonstrated with DUPIXENT in monotherapy trials1,3
51%
of adults treated with DUPIXENT (n=224) achieved ≥75% improvement in lesion extent and severity (EASI-75; secondary endpoint) vs 15% with placebo at Week 16 in SOLO 1 (n=224; P<0.001)
44%
of adults treated with DUPIXENT (n=233) achieved ≥75% improvement in lesion extent and severity (EASI-75; secondary endpoint) vs 12% with placebo at Week 16 in SOLO 2 (n=236; P<0.001)
≥90% skin improvement at 1 year
Concomitant therapy with TCS
EASI-90
(post hoc analysis)2,a-c
Definitive conclusions cannot be made for EASI-90 at Week 52, as this was a post
hoc analysis in which data were
not multiplicity controlled.
aAs in the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.
bFull Analysis Set includes all subjects randomized.
cIn CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.
dWeek 52 data were limited to patients completing 52 weeks as of the cutoff date.
9 OF 10 DUPIXENT monotherapy responders at Week 16
experienced no flares at 1 year
18+ YEARS
PATIENTS EXPERIENCING NO FLARES
(post hoc
analysis)5,e
Definitive conclusions cannot be made for results at Week 52, as this was a post hoc analysis in which data were
not multiplicity controlled.
Q8W, once every 8 weeks; TCI, topical calcineurin inhibitors.
eFlare defined as worsening of disease requiring escalation of treatment.
fAt the end of SOLO 1 and SOLO 2 (Week 16), adult patients achieving IGA 0 or 1 and/or EASI-75 could enroll in SOLO CONTINUE, a double-blind phase 3 study.
Patients who received DUPIXENT 300 mg Q2W in either parent study were rerandomized to DUPIXENT 300 mg Q2W (n=80), DUPIXENT 300 mg Q4W (n=41),
DUPIXENT 300 mg Q8W (n=39), or placebo (n=39).
gWeeks correspond to SOLO-CONTINUE study, in continuation of SOLO 1 and 2. Patients who received rescue treatment in SOLO 1 and 2 (including TCS/TCI)
were considered nonresponders.
Measuring the extent and severity of lesional signs of atopic dermatitis
EASI combines the severity of the signs of eczema and the extent of skin involvement.6
The severity of each of
4 eczema signs is
assessed on a scale of
0 to 36
The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6. Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least.6
Each region gets a total region score:
Severity Score x Area Score x Multiplier = Region Score
The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.6,h
An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is a clinically meaningful change.1
hIn patients <8 years of age, the multipliers for the head and neck are 0.2, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.3.
In patients ≥8 years of age, the multipliers for the head and neck are 0.1, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.4.6
READY TO PRESCRIBE DUPIXENT?